{"id":35184,"topic":"peptides","source":"新京报","title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","url":"https://www.bjnews.com.cn/detail/1783926069168273.html","url_hash":"4dff9979d54d8b9f59ee4c19563e79a1d756ca6d","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBkNW1IbDY0WTVtdHlfNmtmVUFIRlpkOGxqNWtHNjFCWWJXSWhod1pqRGZtd3RfbzRpUDNtVEhkNTQtTmFrTjZPVHFQOGp0QnBtdWpDLUtwMDNOay04cGZjZnVPcWY?oc=5\" target=\"_blank\">三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">新京报</font>","content":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪正加快推进在上海闵行区设立三迭纪上海国际研发与生产中心。此前，其全资子公司三迭纪（上海）医药科技有限公司已完成注册，将专注于口服多肽药物的研发、生产及国际合作项目。该中心将借助上海的区位优势、跨国药企资源及国际化人才储备，推动口服多肽药物的研发与产业化进程。\n口服多肽长期面临胃肠道降解、黏膜渗透性低等递送难题，大多依赖注射给药，患者依从性受限。随着慢性病患者基数持续扩大，临床对安全有效的口服多肽药物需求日益迫切。针对这一痛点，三迭纪将口服多肽确立为全新战略重点，致力于以新型递送技术突破给药屏障，并拓展相关技术平台在口服生物大分子药物领域的广泛应用。\n校对 赵琳","image_url":null,"lang":"zh","published_at":"2026-07-13T07:01:00+00:00","fetched_at":"2026-07-13T07:15:12+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪…","cluster_id":null,"extract_retries":1,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.bjnews.com.cn/detail/1783926069168273.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}},"news_item":{"id":35184,"canonical_url":"https://www.bjnews.com.cn/detail/1783926069168273.html","source_url":"https://www.bjnews.com.cn/detail/1783926069168273.html","title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","source_name":"新京报","author":null,"published_at":"2026-07-13T07:01:00+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBkNW1IbDY0WTVtdHlfNmtmVUFIRlpkOGxqNWtHNjFCWWJXSWhod1pqRGZtd3RfbzRpUDNtVEhkNTQtTmFrTjZPVHFQOGp0QnBtdWpDLUtwMDNOay04cGZjZnVPcWY?oc=5\" target=\"_blank\">三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">新京报</font>","full_text":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪正加快推进在上海闵行区设立三迭纪上海国际研发与生产中心。此前，其全资子公司三迭纪（上海）医药科技有限公司已完成注册，将专注于口服多肽药物的研发、生产及国际合作项目。该中心将借助上海的区位优势、跨国药企资源及国际化人才储备，推动口服多肽药物的研发与产业化进程。\n口服多肽长期面临胃肠道降解、黏膜渗透性低等递送难题，大多依赖注射给药，患者依从性受限。随着慢性病患者基数持续扩大，临床对安全有效的口服多肽药物需求日益迫切。针对这一痛点，三迭纪将口服多肽确立为全新战略重点，致力于以新型递送技术突破给药屏障，并拓展相关技术平台在口服生物大分子药物领域的广泛应用。\n校对 赵琳","excerpt":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 503 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","url":"https://www.bjnews.com.cn/detail/1783926069168273.html","summary":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪…","source":"新京报","date":"2026-07-13T07:01:00+00:00","content":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪正加快推进在上海闵行区设立三迭纪上海国际研发与生产中心。此前，其全资子公司三迭纪（上海）医药科技有限公司已完成注册，将专注于口服多肽药物的研发、生产及国际合作项目。该中心将借助上海的区位优势、跨国药企资源及国际化人才储备，推动口服多肽药物的研发与产业化进程。\n口服多肽长期面临胃肠道降解、黏膜渗透性低等递送难题，大多依赖注射给药，患者依从性受限。随着慢性病患者基数持续扩大，临床对安全有效的口服多肽药物需求日益迫切。针对这一痛点，三迭纪将口服多肽确立为全新战略重点，致力于以新型递送技术突破给药屏障，并拓展相关技术平台在口服生物大分子药物领域的广泛应用。\n校对 赵琳","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 503 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/35184","export_markdown":"/api/items/35184/export?format=markdown","export_json":"/api/items/35184/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html"},"formats":{"full":{"id":35184,"title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","url":"https://www.bjnews.com.cn/detail/1783926069168273.html","source":"新京报","author":null,"published_at":"2026-07-13T07:01:00+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪…","full_text":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪正加快推进在上海闵行区设立三迭纪上海国际研发与生产中心。此前，其全资子公司三迭纪（上海）医药科技有限公司已完成注册，将专注于口服多肽药物的研发、生产及国际合作项目。该中心将借助上海的区位优势、跨国药企资源及国际化人才储备，推动口服多肽药物的研发与产业化进程。\n口服多肽长期面临胃肠道降解、黏膜渗透性低等递送难题，大多依赖注射给药，患者依从性受限。随着慢性病患者基数持续扩大，临床对安全有效的口服多肽药物需求日益迫切。针对这一痛点，三迭纪将口服多肽确立为全新战略重点，致力于以新型递送技术突破给药屏障，并拓展相关技术平台在口服生物大分子药物领域的广泛应用。\n校对 赵琳","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 503 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}},"actions":{"read":"/item/35184","export_markdown":"/api/items/35184/export?format=markdown","export_json":"/api/items/35184/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html"}},"digest":{"id":35184,"title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","url":"https://www.bjnews.com.cn/detail/1783926069168273.html","source":"新京报","topic":"peptides","published_at":"2026-07-13T07:01:00+00:00","excerpt":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。 本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。 依托本轮融资，三迭纪…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 503 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","subtitle":"新京报 · 2026-07-13","summary":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。 本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。…","badges":["quality:high"],"links":{"read":"/item/35184","original":"https://www.bjnews.com.cn/detail/1783926069168273.html","diagnose":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html"},"quality_warning":null},"export":{"title":"三迭纪完成新一轮战略融资，将用于国际研发与生产中心建设等 - 新京报","url":"https://www.bjnews.com.cn/detail/1783926069168273.html","summary":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪…","source":"新京报","date":"2026-07-13T07:01:00+00:00","content":"新京报讯（记者王卡拉）7月13日，中国唯一持有3D打印药物生产许可证的三迭纪（南京）医药科技股份有限公司（以下简称“三迭纪”）宣布，公司完成新一轮战略融资，融资将用于上海国际研发与生产中心的建设、口服多肽管线的临床推进以及国际合作业务的拓展。\n本轮融资的投资方包括上海市闵行区金融投资发展有限公司、上海临港数科私募基金管理有限公司等。杭州产投集团有限公司亦参与本轮交易，并计划后续与三迭纪进一步探讨更多方向的战略合作。\n依托本轮融资，三迭纪正加快推进在上海闵行区设立三迭纪上海国际研发与生产中心。此前，其全资子公司三迭纪（上海）医药科技有限公司已完成注册，将专注于口服多肽药物的研发、生产及国际合作项目。该中心将借助上海的区位优势、跨国药企资源及国际化人才储备，推动口服多肽药物的研发与产业化进程。\n口服多肽长期面临胃肠道降解、黏膜渗透性低等递送难题，大多依赖注射给药，患者依从性受限。随着慢性病患者基数持续扩大，临床对安全有效的口服多肽药物需求日益迫切。针对这一痛点，三迭纪将口服多肽确立为全新战略重点，致力于以新型递送技术突破给药屏障，并拓展相关技术平台在口服生物大分子药物领域的广泛应用。\n校对 赵琳","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.bjnews.com.cn/detail/1783926069168273.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 503 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 503 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":503,"summary_length":221,"usable_text_length":503,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":1,"content_length":503,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}